01—Abstract
Summary
Summary of the 10-Q filed July 30, 2026. Cited figures are marked; the original filing is the authoritative source.
The Cigna Group's Q2 2026 10-Q shows a quarter of solid top-line and earnings growth, led by Cigna Healthcare.
Total revenues rose 7% to $71.7 billiona for the quarter and 6% to $140.2 billion for the six months. Shareholders' net income grew 8% to $1.66 billion ($6.29 diluted EPS, up 10%), and adjusted income from operations rose 6% to $2.05 billion ($7.78 adjusted EPS, up 8%). Growth was driven mainly by Cigna Healthcare, where pre-tax adjusted income rose 17% on better U.S. Employer margins and premium rate increases, while Evernorth was flat for the half year (-2% in the quarter) as Pharmacy Benefit Services income fell 27% on client- and customer-focused initiatives, partly offset by Specialty and Care Services growth of 22%.
The balance sheet and cash flow picture is more mixed. Operating cash flow was only $710 millionb for the first six months versus $34 million a year earlier, but this was largely driven by working-capital timing and factoring facilities, and pharmacy payables fell $4.1 billion. Short-term debt rose to $2.8 billion from $0.6 billion, while long-term debt declined to $29.1 billion.
The debt-to-capitalization ratio improved slightly to 42.8% from 43.0%. Capital returns were much lighter than last year, with $250 millionc of buybacks versus $2.6 billion in the prior-year period, and quarterly dividends were maintained at $1.56 per share. Other comprehensive loss of $1.6 billion for the half year, driven by discount-rate changes on long-duration liabilities, pushed accumulated other comprehensive loss to $4.4 billion.
Investors should also note the April 2026 announced exit from the Individual and Family Plans medical business effective January 1, 2027, a $450 milliond strategic optimization program cost year-to-date (program costs expected to continue through 2028), and litigation charges of $77 million in the quarter. The HCSC divestiture of Medicare Advantage in March 2025 continues to depress year-over-year comparisons for premiums and medical costs.
02—Key points
Key Highlights
- Total revenues up 7% to $71.7B in Q2 2026 and 6% to $140.2B for H1 2026; pharmacy revenues rose 7% in the quarter, premiums rose 8%, and fees rose 6%.
- Shareholders' net income up 8% to $1.66B in Q2 (diluted EPS $6.29, +10%); H1 net income up 16% to $3.31B (diluted EPS $12.55, +19%).
- Adjusted income from operations up 6% to $2.05B in Q2 (adjusted EPS $7.78, +8%); H1 adjusted EPS $15.58, up 12%.
- Cigna Healthcare pre-tax adjusted income rose 17% in both Q2 and H1, with adjusted revenues up 9% in Q2 on premium rate increases; H1 revenues were down 8% due to the HCSC Medicare Advantage divestiture.
- Evernorth pre-tax adjusted income fell 2% in Q2 as Pharmacy Benefit Services income dropped 27% from client initiatives, partly offset by Specialty and Care Services income up 22%.
- Operating cash flow of $710M in H1 2026 vs. $34M in H1 2025, aided by receivables timing and factoring, though pharmacy payables declined $4.1B.
- Capital return slowed sharply: $250M of share repurchases in H1 2026 vs. $2.6B a year earlier; Q3 dividend of $1.56/share declared July 22, 2026, and short-term debt increased to $2.8B.
03—Questions
Frequently Asked Questions
How did Cigna's earnings perform in the second quarter of 2026?
Shareholders' net income rose 8% to $1.66 billion, or $6.29 per diluted share (up 10%). Adjusted income from operations rose 6% to $2.05 billion, or $7.78 per diluted share (up 8%). The increase was driven mainly by Cigna Healthcare, which saw pre-tax adjusted income rise 17%, while Evernorth's pre-tax adjusted income declined 2%.
What is driving the weakness in Evernorth's Pharmacy Benefit Services segment?
Pre-tax adjusted income from Pharmacy Benefit Services fell 27% in both the quarter and the half year, primarily reflecting client- and customer-focused initiatives (down 11% in Q2 and 9% for H1) and lower pharmacy claim volume (down 2%). Specialty and Care Services partially offset this with income growth of 22% in Q2.
Why did operating cash flow improve so much year over year, and is it sustainable?
Operating cash flow was $710 million for H1 2026 versus $34 million in H1 2025. Management attributes the improvement mainly to accounts receivable timing and factoring facility settlements, partially offset by Inflation Reduction Act cash impacts and lower insurance liabilities. Because much of the improvement reflects working-capital timing, it may not be repeated consistently, and pharmacy payables actually declined $4.1 billion in the period.
What are the notable changes in Cigna's capital allocation and balance sheet?
Share repurchases fell to $250 million in H1 2026 from $2.6 billion a year earlier, while the quarterly dividend was maintained at $1.56 per share. Short-term debt rose to $2.8 billion from $0.6 billion, and long-term debt declined to $29.1 billion after a $550 million note repayment. The debt-to-capitalization ratio improved slightly to 42.8%, and the company retains $6.5 billion of undrawn revolver capacity.
What strategic and operational changes should investors be aware of?
Cigna announced in April 2026 that it will exit the Individual and Family Plans medical business effective January 1, 2027. The strategic optimization program, expected to run through 2028, has cost $450 million year to date, mainly severance. Litigation charges of $77 million were recorded in Q2, and Evernorth is making client-focused initiatives tied to its rebate-free model and recontracting efforts.
04—Continue